Protara Therapeutics
TARA
29 hedge funds and large institutions have $75.8M invested in Protara Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.27% less ownership
Funds ownership: 51.53% → 49.26% (-2.3%)
9% less funds holding
Funds holding: 32 → 29 (-3)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
84% less capital inflows, than outflows
Capital inflows: $591K | Capital outflows: $3.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
+$195K |
| 2 |
Deerfield Management
New York
|
+$162K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$113K |
| 4 |
Spark Investment Management
New York
|
+$101K |
| 5 |
Walleye Trading
New York
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$2.95M |
| 2 |
Paloma Partners
Greenwich,
Connecticut
|
-$234K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$206K |
| 4 |
Millennium Management
New York
|
-$124K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$108K |
TARA Hedge Fund Activity: Q3 2016 in Review
29 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2016, worth a combined $75.8M — down 18% from $93M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TARA and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $195K. The largest seller was Tiverton Asset Management, cutting an estimated $2.95M.
- 29 institutional investors held Protara Therapeutics (TARA) as of Q3 2016, down from 32 in Q2 2016.
- Funds reported $75.8M of Protara Therapeutics stock for Q3 2016, down 18% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q3 2016 and 7 closed out, a net change of -3 holders.
- The largest Protara Therapeutics buyer in Q3 2016 was Bridgeway Capital Management, an estimated $195K added.
- The largest Protara Therapeutics seller in Q3 2016 was Tiverton Asset Management, an estimated $2.95M sold.
Based on aggregated 13F filings for Q3 2016.